Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. (Q38459634)
Jump to navigation
Jump to search
scientific article published on 14 December 2012
Language | Label | Description | Also known as |
---|---|---|---|
English | Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. |
scientific article published on 14 December 2012 |
Statements
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial (English)
Antonio Palumbo
Michel Delforge
Maria T Petrucci
Martin Kropff
Philip Lewis
Annabel Nixon
Jingshan Zhang
14 December 2012